Indivior PLC announced that Dr. David Wheadon, who will join the Board as an Independent Non-Executive Director on June 1, 2024, has been appointed as a member of the Nomination, Remuneration and Science Committees also with effect from June 1, 2024. Furthermore, in order to comply with Nasdaq's listing rule that requires the Nomination Committee be comprised solely of Independent Directors, Jerome Lande has advised the Board that he will step down as a member of the Nomination Committee with effect from May 31, 2024. Mr. Lande is a Representative Director of Scopia Capital Management LP, who are a significant shareholder of the Group.

Following these changes, the membership of the Nomination, Remuneration and Science Committees will be as follows: Nomination Committee: Graham Hetherington (Chair; Peter Bains; Joanna Le Couilliard; Dr. Keith Humphreys; Barbara Ryan; Mark Stejbach; Juliet Thompson; Dr. David Wheadon. Remuneration Committee: Joanna Le Couilliard (Chair); Peter Bains; Graham Hetherington; Barbara Ryan; Dr. David Wheadon. Science Committee: Peter Bains (Chair); Dr. Keith Humphreys; Barbara Ryan; Mark Stejbach; Dr. David Wheadon.